SecBot SecBot
PRESS-RELEASE ·Filed Apr 16, 2026

EVAX

Evaxion
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

No immediate trading implications. Monitor upcoming clinical trial updates or financing announcements, which would be more material catalysts for this micro-cap biotech.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.14
T+0 close · Apr 16, 2026 · via day close
Latest settled
−27.05%
T+60 · $3.02
Vs SPY
−34.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $4.14entry
  2. T+1 · 7mo ago +7.49%α +6.27% · $4.45
  3. T+5 · 7mo ago +2.66%α +1.67% · $4.25
  4. T+20 · 6mo ago +0.48%α −5.33% · $4.16
  5. T+60 · 4mo ago −27.05%α −34.10% · $3.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board members while adding one new director. The filing is a routine corporate governance update with no material financial or strategic developments disclosed.

Key Facts

  • Annual General Meeting held on April 16, 2026
  • 2025 Annual Report approved
  • Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda re-elected to Board
  • Jens Bitsch Nørhave newly elected to Board
  • No changes to executive leadership or company strategy announced

Financial Impact

No financial impact

Risk Factors

  • Forward-looking statements highlight risks related to funding needs and clinical development
  • Small market cap ($35M) increases volatility and sensitivity to future dilution

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3275638

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026